Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Sold by Kings Path Partners LLC

Kings Path Partners LLC lowered its position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 38.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,161 shares of the medical instruments supplier's stock after selling 2,615 shares during the period. Kings Path Partners LLC owned about 0.08% of Mesa Laboratories worth $494,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Amundi increased its holdings in shares of Mesa Laboratories by 81.6% during the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after purchasing an additional 297 shares during the period. Resona Asset Management Co. Ltd. bought a new stake in shares of Mesa Laboratories during the fourth quarter valued at approximately $92,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Mesa Laboratories in the 4th quarter worth about $132,000. Tower Research Capital LLC TRC grew its holdings in Mesa Laboratories by 72.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,328 shares of the medical instruments supplier's stock worth $175,000 after buying an additional 560 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in Mesa Laboratories in the 4th quarter worth about $205,000. Institutional investors own 90.60% of the company's stock.

Mesa Laboratories Stock Up 3.0%

Shares of NASDAQ MLAB traded up $2.97 during midday trading on Tuesday, hitting $100.93. The stock had a trading volume of 10,504 shares, compared to its average volume of 39,930. The business's 50 day moving average is $114.78 and its 200-day moving average is $126.29. The company has a market cap of $550.57 million, a P/E ratio of -2.18 and a beta of 0.97. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $155.12. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Stockholders of record on Friday, May 30th will be issued a dividend of $0.16 per share. The ex-dividend date is Friday, May 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.63%. Mesa Laboratories's payout ratio is -172.97%.

Insider Buying and Selling at Mesa Laboratories

In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the completion of the transaction, the chief executive officer now owns 43,337 shares in the company, valued at $5,369,887.67. This trade represents a 32.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MLAB. Wall Street Zen downgraded shares of Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a report on Friday. Wells Fargo & Company decreased their target price on shares of Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating on the stock in a research report on Friday.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.